HIV / AIDS

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.

Among mpox patients treated with tecovirimat, there was no difference in treatment outcomes between those living with HIV and those without HIV.

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.

The 340B program has had a great impact on access to HIV treatment and prevention services in the US.

When taken within 3 days, doxycycline given post-exposure (doxy-PEP) decreased the incidence rates of syphilis, gonorrhea, and chlamydia significantly.

ViiV Healthcare is working with 3 companies to manufacture generic versions of cabotegravir long-acting (LA).

The virus can maintain a reservoir in these white blood cells even in those who have been virally suppressed for years.

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

Using a pregnant rabbit model, investigators found a robust antigen-specific antibody response in pregnant rabbits against HIV and Zika virus.

The patient, referred to as the “New York patient,” was treated with stem cells from cord blood, and has remained HIV-free in her blood since her transplant in 2017.

The Wistar Institute’s Amelia Escolano, PhD, is developing a novel approach using sequential immunization to capture protection against multiple strains.

The federal agency has taken a vital role in support and implementation of the ongoing PEPFAR initiative.

“HIV reservoir dynamics are driven by local inflammation and gut dysbiosis,” the investigators concluded.

Gut microbial abundance was observed to be independent of age and influenced COVID-19 spike IgG levels.

Primary care physicians and advanced practice providers are responsible for the majority of people seeking medical care in the United States, yet there is a gap in discussing sexual health for those who are at risk of HIV or other sexually-transmitted diseases.

“The combination of the 2 drugs was shown in this trial to be noninferior to the standard 3-drug regimen,” said Jean Michel Molina, MD, PhD, lead investigator of Merck’s islatravir/doravirine study.

This fungal infection is an example of either being a treatable ailment or one that can cause severe disease and death depending on access to diagnostic and treatment resources.

Investigators looked at people living with HIV (PLWH) and the impact of this form of medication on potential cardiovascular events.

Here's a recap of our most newsworthy coverage of the CROI 2023 conference.

At the CROI conference, AELIX Therapeutics announced positive topline results for a phase 2a clinical trial.

“Patients deserve more than just viral suppression,” said Harmony Garges, MD, chief medical officer of ViiV Healthcare.

“We should test everybody,” said Charles Béguelin, noting that the vast majority of hepatitis D infections go undetected.

Here is an overview of highly anticipated HIV trial data ViiV Healthcare will share next week at the CROI 2023 conference.

Among male couples, HIV PrEP usage is suboptimal. Lingering stigma may be preventing men who have sex with men from using PrEP, even when in a relationship with an HIV-positive partner.

February 7 is National Black HIV/AIDS Awareness Day (#NBHAAD). In observance, we're recapping stories to raise awareness and work toward ending HIV/AIDS disparities in Black communities.